GS UHL (Votrient pazopanib 400 mg)
Generic Name: pazopanib
Pill with imprint GS UHL is Yellow, Capsule-shape and has been identified as Votrient pazopanib 400 mg. It is supplied by GlaxoSmithKline.
Votrient is used in the treatment of renal cell carcinoma; soft tissue sarcoma and belongs to the drug class VEGF/VEGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Votrient pazopanib 400 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for GS UHL
Votrient
- Generic Name
- pazopanib
- Imprint
- GS UHL
- Strength
- pazopanib 400 mg
- Color
- Yellow
- Shape
- Capsule-shape
- Availability
- Prescription only
- Drug Class
- VEGF/VEGFR inhibitors
- Pregnancy Category
- D - Positive evidence of risk
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- GlaxoSmithKline
- National Drug Code (NDC)
More about Votrient (pazopanib)
- Side effects
- Drug interactions
- Dosage information
- During pregnancy or Breastfeeding
- Reviews (80)
- Drug images
- Compare alternatives
- Pricing & coupons
- En español
- Drug class: VEGF/VEGFR inhibitors
- FDA approval history
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.